TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Stock Börse Stuttgart
Equities
TKDA
US8740602052
Pharmaceuticals
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.15 EUR | +1.25% |
|
0.00% | -6.20% |
| Jul. 09 | Takeda Issues New Shares, Disposes of Treasury Shares Under Incentive Scheme | MT |
| Jul. 03 | Blackstone selling Japan drugmaker Alinamin to MBK Partners | RE |
| Sales 2025 * | 4,289B 26.55B 24.49B | Sales 2026 * | 4,354B 26.95B 24.86B | Capitalization | 6,736B 41.69B 38.46B |
|---|---|---|---|---|---|
| Net income 2025 * | 115B 710M 655M | Net income 2026 * | 216B 1.34B 1.23B | EV / Sales 2025 * | 2.53 x |
| Net Debt 2025 * | 4,109B 25.43B 23.46B | Net Debt 2026 * | 3,849B 23.82B 21.98B | EV / Sales 2026 * | 2.43 x |
| P/E ratio 2025 * |
58.8
x | P/E ratio 2026 * |
31.2
x | Employees | 49,281 |
| Yield 2025 * |
4.59% | Yield 2026 * |
4.69% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
| 1 day | +1.25% | ||
| Current month | -10.37% | ||
| 6 months | -5.47% | ||
| Current year | -6.20% |
Current year
12.10
13.50
1 year
12.1013.50
3 years
12.1014.60
5 years
12.0018.70
10 years
12.0018.70
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
| Chief Tech/Sci/R&D Officer | 69 | 15-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-11 | 12.1 | +0.83% | 0 |
| 24-07-10 | 12 | 0.00% | 0 |
| 24-07-09 | 12 | 0.00% | 0 |
| 24-07-08 | 12 | +0.84% | 0 |
| 24-07-05 | 11.9 | -0.83% | 0 |
Delayed Quote Börse Stuttgart, July 11, 2024 at 02:14 am EDT
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,250
JPY
Average target price
4,744
JPY
Spread / Average Target
+11.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.22% | 846B | |
| +39.29% | 628B | |
| -4.66% | 360B | |
| +16.77% | 322B | |
| +8.50% | 297B | |
| +14.08% | 240B | |
| +18.11% | 223B | |
| +3.19% | 224B | |
| +11.68% | 173B |
- Stock Market
- Equities
- 4502 Stock
- TKDA Stock
